



# Clinical Risk Factors Associated with Anti-Epileptic Drug Responsiveness in Canine Epilepsy

Rowena M. A. Packer<sup>1</sup>, Nadia K. Shihab<sup>1,2</sup>, Bruno B. J. Torres<sup>1,3</sup>, Holger A. Volk<sup>1\*</sup>

**1** Department of Clinical Science and Services, Royal Veterinary College, Hatfield, Hertfordshire, United Kingdom, **2** Department of Neurology/Neurosurgery, Southern Counties Veterinary Specialists, Ringwood, Hampshire, United Kingdom, **3** Department of Veterinary Medicine and Surgery, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

## Abstract

The nature and occurrence of remission, and conversely, pharmacoresistance following epilepsy treatment is still not fully understood in human or veterinary medicine. As such, predicting which patients will have good or poor treatment outcomes is imprecise, impeding patient management. In the present study, we use a naturally occurring animal model of pharmacoresistant epilepsy to investigate clinical risk factors associated with treatment outcome. Dogs with idiopathic epilepsy, for which no underlying cause was identified, were treated at a canine epilepsy clinic and monitored following discharge from a small animal referral hospital. Clinical data was gained via standardised owner questionnaires and longitudinal follow up data was gained via telephone interview with the dogs' owners. At follow up, 14% of treated dogs were in seizure-free remission. Dogs that did not achieve remission were more likely to be male, and to have previously experienced cluster seizures. Seizure frequency or the total number of seizures prior to treatment were not significant predictors of pharmacoresistance, demonstrating that seizure density, that is, the temporal pattern of seizure activity, is a more influential predictor of pharmacoresistance. These results are in line with clinical studies of human epilepsy, and experimental rodent models of epilepsy, that patients experiencing episodes of high seizure density (cluster seizures), not just a high seizure frequency pre-treatment, are at an increased risk of drug-refractoriness. These data provide further evidence that the dog could be a useful naturally occurring epilepsy model in the study of pharmacoresistant epilepsy.

**Citation:** Packer RMA, Shihab NK, Torres BBJ, Volk HA (2014) Clinical Risk Factors Associated with Anti-Epileptic Drug Responsiveness in Canine Epilepsy. PLoS ONE 9(8): e106026. doi:10.1371/journal.pone.0106026

**Editor:** Giuseppe Biagini, University of Modena and Reggio Emilia, Italy

**Received:** April 7, 2014; **Accepted:** July 29, 2014; **Published:** August 25, 2014

**Copyright:** © 2014 Packer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its Supporting Information files.

**Funding:** The authors have no funding or support to report.

**Competing Interests:** Nadia K. Shihab is employed by Southern Counties Veterinary Specialists. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

\* Email: hvolk@rvc.ac.uk


¶ NKS and BBJT are joint second authors on this work.

## Introduction

Epilepsy is the most common chronic neurological condition in humans and dogs, with estimated prevalences of 0.4–1% [1] and 0.6%, respectively [2]. In human medicine, the best improvement in Quality of Life (QoL) for epilepsy patients is achieved when treatment leads to remission (seizure freedom) [3–5]. Indeed, in one study, no significant change in QoL was found after treatment for subjects that did *not* achieve seizure freedom [4]. In addition to anti-epileptic drug (AED) therapy, surgical interventions are utilised to achieve seizure freedom in medically intractable cases [6]. The dog has been considered as a naturally occurring model of human epilepsy [7,8]. There are considerable parallels in the diagnosis of human and canine epilepsy, with similarly high levels of workup, for example and the use of advanced diagnostic imaging and in limited cases, the use of electroencephalography (EEG) [9]. However, in veterinary medicine, most epilepsy trials have primarily focused on reducing seizure frequency, rather than achieving seizure freedom. Indeed, an  $\geq 50\%$  reduction in seizure frequency has been the definition of AED efficacy in the majority of canine epilepsy studies (e.g. [10–17]). This may not be a

satisfactory outcome for the carers (the owners), with nearly one third considering only complete seizure freedom as an acceptable outcome [18]. More than two thirds of dogs with epilepsy will continue to have seizures long-term [19–22] and around 20–30% will remain poorly controlled (<50% reduction of seizure frequency) despite adequate treatment with phenobarbitone (PB) and/or potassium bromide (KBr) [23–25]. Consequently, there is a need to identify those dogs that are likely to have poor outcomes so that owners have realistic, evidence-based expectations of their dog's treatment. This has been an area of focus in human epilepsy, with analyses identifying risk factors for pharmacoresistance and poor outcome (e.g. [26–28]). In contrast, it has been recognised that more epidemiologic studies are needed to further document the nature and occurrence of remission of epilepsy in dogs [29], and identify risk factors associated with positive and negative outcomes. For those dogs that are unresponsive to AEDs, 'alternative' non-pharmacological treatment options need to be developed to improve their quantity and quality of life, for example, dietary and surgical interventions [30].

Remission with or without medication has been observed in canine epilepsy cases, demonstrating that epilepsy in dogs is not



necessarily a lifelong condition. Remission rates vary between studies, for example in a study of Danish Labrador Retrievers, 24% of dogs were classed as being in remission; with only 1 (6%) of these receiving antiepileptic treatment (drug-induced remission) [21]. In a further Danish study of 63 dogs with epilepsy, the remission rate (both spontaneous remission and remission with treatment) was 15% [22]. In these studies, remission was classified as being seizure free for two years or three years seizure free, respectively. In a Swiss study of Labrador Retrievers, 30% of dogs treated with phenobarbitone became seizure-free, with an average follow-up period of 4.8 years [19]. In a study of the efficacy of phenobarbital compared with KBr as a first line treatment, complete seizure freedom was achieved in 85% and 52%, respectively, of treated dogs [31]. This study only lasted for six months however, and it is possible that the percentage of dogs experiencing seizure freedom would be lower given a longer follow-up period. In addition, higher % treatment success rates may reflect studying animals in first opinion practice environment, where seizure phenotypes are likely to be less severe than animals seen at referral practices.

Several factors related to the natural history of the disease and clinical factors have been implicated in both the experimental and clinical literature as influencing the likelihood of successful treatment with AEDs (either remission or <50% reduction in seizure frequency). For example, recent rodent studies found that early treatment [32] had a positive influence on the likelihood of remission being achieved in certain types of epilepsy. Indeed, in human epilepsy it was thought that patients should be treated with AEDs immediately after a seizure to increase the likelihood of achieving remission. However, evidence that remission rates in countries with and without ready access to AEDs are similar [33] implies that AEDs may act to suppress seizures, but have no influence on achieving remission. In addition, there is increasing evidence from both canine, rodent and human studies, that other aspects of disease e.g. different markers of severity *can* influence drug responsiveness and treatment outcome [19,29,34–36]. This includes a high seizure frequency before treatment, and the presence of cluster seizures and/or status epilepticus. Much of the canine epilepsy literature in this area is derived from single breed studies, thus the aim of this retrospective study was to investigate factors associated with remission in a large population of dogs with epilepsy treated at a multi-breed canine specific epilepsy clinic.

## Materials and Methods

Data from dogs treated at a multi-breed canine specific epilepsy clinic at the Royal Veterinary College Small Animal Referral Hospital (RVC SARH) between 2005–2011 was retrospectively collected from RVC's electronic patient records. Clinical data was originally gained via standardised owner questionnaires for epilepsy patients at their first appointment, and longitudinal follow up data was gained via telephone interview with the dogs' owners. All dogs received a uniform diagnostic protocol (including complete blood cell count; serum biochemical profile and dynamic bile acid testing; MRI of the brain, 1.5-Tesla Gyroscan NT, Philips Medical Systems) and a neurological examination to rule out an underlying cause of the seizure activity. Only dogs which were reported in the records to be diagnosed with idiopathic epilepsy, for which a cause was not identified (no remarkable findings on interictal neurological examination, haematology, biochemistry, brain magnetic resonance imaging and cerebrospinal fluid examination), were included in the study. A genetic or hereditary basis cannot be confirmed for every case included in the study, and it is possible that the cause could have been identified

with continuous EEG recording. Only dogs receiving AEDs were included in the study.

Seizures were classified according to the former guidelines of the International League Against Epilepsy, modified for veterinary patients (Berendt and Gram, 1999; Licht et al., 2002). Epilepsy was defined of at least two unprovoked seizures >24 h apart. Cluster seizures were defined as an episode where more than one seizure occurred within a 24 h period, with full recovery of consciousness between seizures. Status epilepticus was defined as seizure activity lasting longer than 10 min without gaining consciousness. Seizure activity lasting less than 10 min without gaining consciousness was classed as a single seizure episode. A consistent history was collected with the help of a questionnaire developed for a previous study [10]. The data collected included: signalment, age presented to the hospital (days), age of dog at the time of the first seizure (days), time until diagnosis (days), duration of the disorder before treatment (days), number of seizures prior to any treatment with an AED, seizure frequency per month before medication, type of seizures experienced, and experience of cluster seizures (yes/no) and status epilepticus (yes/no). Medication administered was recorded, specifically whether phenobarbitone (PB), potassium bromide (KBr) or other 3<sup>rd</sup> line drugs were prescribed, and response to these drugs recorded as responsive or unresponsive. Follow up time was recorded in days. Treatment success was recorded as:

- (i) Seizure-free remission (with or without medication) (1/0)
- (ii)  $\geq 50\%$  reduction in seizure frequency (1/0)

Non-responsiveness to an AED was classified as a less than 50% reduction in seizure frequency, despite being within the reference range for the prescribed AED(s) and titrated to the maximum tolerated effective dose. As these data were derived from a clinical population, decision-making leading to the maximum dose of any AED was made by both the clinician and the owner, taking into account adverse effects of the drug and its efficacy. Serum levels of phenobarbitone and/or potassium bromide were checked by the attending clinician, and recorded from the clinical records where available, to ensure the dog was within the reference range for these AEDs and receiving adequate therapy, and to test the effect of this variable.

## Ethics statement

This study was approved by the Royal Veterinary College's Ethics and Welfare Committee. The owners of the dogs gave permission for their animals to be used in this study.

## Statistical analysis

Differences between outcome variables were tested with a Fisher's exact test for categorical variables with expected values < 10, and the Pearson's chi squared test for expected values >10. The Mann-Whitney U-test was used for continuous variables. Generalised linear mixed models for binary outcomes were then used to identify risk factors in a multivariate analysis for successful treatment outcomes, using the lmer function in R from the lme4 package. Treatment outcomes (i) seizure free remission with or without medication (1/0) and (ii)  $\geq 50\%$  reduction in seizure frequency (1/0) were used as the response variables in models. Follow-up time and serum AED values were tested in the models to verify that they did not have an effect on treatment success. Breed was included as a random effect, with all cross breeds coded plainly as 'cross breed' due to the unknown parentage of many of these dogs. This random effect took into account the genetic non-independence of multiple members of the same breed in the study

**Table 1.** Association between clinical variables and being in seizure-free remission in canine epilepsy patients.

		Remission		Statistics	
		No (%)	Yes (%)	Fishers exact (2 sided)	P
Sex	Male	75.1	53.6	5.56	0.024
	Female	24.9	46.4		
Neuter status	Neutered	53.2	75.0	4.53	0.038
	Entire	46.8	25.0		
Seizure severity	Status epilepticus	20.0	0.0	0.25	0.802
	No Status epilepticus	80.0	100.0		
	Cluster seizures	62.8	17.9		
	No Cluster seizures	37.2	82.1		
		Median (25 <sup>th</sup> –75 <sup>th</sup> percentile)	Median (25 <sup>th</sup> –75 <sup>th</sup> percentile)	Mann Whitney U	P
Age presented to hospital (days)		1080 (720–1800)	1440 (1080–2085)	1933	0.61
Time until diagnosis (days)		180 (62.3–378.8)	90 (15–225)	1204	0.79
Age at onset seizures (days)		720 (441–1286)	1170 (720–1725)	2971	0.026
Duration of disorder before treatment (days)		90 (30–180)	60 (26–120)	578	0.31
Number of seizures before start of treatment		5 (3–8.5)	4 (3–5.3)	1286	0.09
Seizure frequency per month before medication		3 (1–6)	2 (1.25–3.75)	1582	0.39

doi:10.1371/journal.pone.0106026.t001

population, and possible demographic and environmental factors. Predictors including age, sex and neuter status were tested in all models. Multicollinearity was checked for in all models, identified from inflated standard errors in the models, and thus avoided. Model fit was assessed using the deviance and Akaike's information criterion. Data is presented as median with 25<sup>th</sup> and 75<sup>th</sup> percentiles and all tests were used two-sided with  $P < 0.05$  being considered statistically significant.

## Results

### Population demographics

122 dogs were lost to follow and 344 dogs were included in the analysis, of which 89.5% were pure bred and 10.5% were cross-breeds. The five most common breeds were the Labrador Retriever (14.8%), cross breed (10.5%), Border Collie (9.9%), German Shepherd Dog (8.7%) and the Staffordshire Bull Terrier (5.5%). The majority of dogs were male (70.3%), with 57% of all dogs neutered. The median age (in days) at presentation to the small animal referral hospital was 1260 days (720–2008) (approximately 3.5 years).

### Clinical data

The median age at onset of seizures was 780 days (360–1447.5). The median time until diagnosis was 150 days (38–360), with the median duration of the disorder before treatment 67.5 days (30–180). The median number of seizures before the start of treatment was 4.5 (3–7.25) with a median seizure frequency (per month) before medication of 3 (1–5). The median follow up time was 656 days (330–960).

A minority of dogs had experienced status epilepticus (13.1%), whereas nearly half of dogs had experienced cluster seizures (48%). There was a significant association between the presence of status epilepticus and cluster seizures ( $X^2 = 8.05$ ,  $P = 0.004$ ), with 9.8% of dogs experiencing both status epilepticus and cluster seizures. There was no difference between male and female dogs experiencing cluster seizures (48.9% *vs.* 45.8%;  $X^2 = 0.26$ ,  $P = 0.61$ ); however, more male dogs experienced status epilepticus than female dogs (15.5% *vs.* 5.2%;  $X^2 = 4.12$ ,  $P = 0.041$ ). At the univariate level (Table 1) dogs without cluster seizures were significantly more likely to go into remission, but there was no difference in dogs with or without status epilepticus.

The most common seizure type was complex-focal seizures with secondary tonic-clonic generalisation (35.7%), followed by generalised tonic-clonic (32.6%), complex-focal (14.1%), and simple-focal seizures with secondary tonic-clonic generalisation (13.7%). The rarest seizure type was simple-focal seizures with only 11 cases (3.8%).

Of the 113 dogs for which PB concentrations were available, they were well within the reference range ( $29.1 \pm 1.60$   $\mu\text{g/ml}$ , reference range from our laboratory of 15–45  $\mu\text{g/ml}$ ). KBr concentrations were available for 53 dogs and were  $1.61 \pm 0.11$   $\text{mg/ml}$ , again well within the reference range from our laboratory of 0.5–1.9  $\text{mg/ml}$ .

The majority of dogs were receiving PB at follow up (67.2%), with a further 38.4% of cases receiving KBr, and 27% of all cases receiving PB and KBr in combination. A minority of cases (10.2%) were prescribed a third line AED (e.g. gabapentin, pregabalin, levetiracetam and zonisamide). In addition, 5.4% of cases received

**Table 2.** Association between clinical variables and  $\geq 50\%$  reduction in seizure frequency in canine epilepsy patients.

		$\geq 50\%$ reduction		Statistics			
		No (%)	Yes (%)	Fishers exact (2 sided)	P		
Sex	Male	78.5	64.5	5.54	0.025		
	Female	21.5	35.5				
Neuter status	Neutered	50.0	63.2	3.62	0.040		
	Entire	50.0	36.8				
Seizure severity	Status epilepticus	21.1	10.2	4.35	0.052		
	No Status epilepticus	78.9	89.8				
	Cluster seizures	71.7	33.5			34.01	<0.001
	No Cluster seizures	28.3	66.5				
		Median (25 <sup>th</sup> –75 <sup>th</sup> percentile)	Median (25 <sup>th</sup> –75 <sup>th</sup> percentile)	Mann Whitney U	P		
Age presented to hospital (days)		990 (720–1514.8)	1424.5 (840–2094.5)	5795	0.011		
Time until diagnosis (days)		183 (72.5–360)	150 (34–360)	4225.5	0.216		
Age at onset seizures (days)		720 (360–1125)	968 (447.8–1699)	9893	0.007		
Duration of disorder before treatment (days)		37.5 (22.5–142.5)	90 (30–180)	833.5	0.064		
Number of seizures before start of treatment		5 (3.3–8.8)	4.5 (3–7.8)	2762	0.276		
Seizure frequency per month before medication		3 (1–5)	2 (1–5)	5022.5	0.569		

doi:10.1371/journal.pone.0106026.t002

emergency rectal diazepam treatment and 8.1% received pulsed intermittent treatment with levetiracetam.

### Risk factors for remission

Fourteen per cent of dogs were in remission on PB treatment. When  $\geq 50\%$  reduction in seizure frequency is used as the outcome measure, success rates are markedly higher with 64.5% of dogs achieving this level of seizure reduction. At the univariate level, several factors were associated with an increased likelihood of achieving remission (Table 1), namely: being female, neutered, no previous experience of cluster seizures and an older age at onset of seizures. The same four factors were also associated with an increased likelihood of achieving an  $\geq 50\%$  reduction in seizure frequency, with the addition of an older age at presentation to hospital (Table 2).

When tested in a multivariate mixed model (Table 3), two categorical variables were significantly associated with the likelihood of remission being achieved; sex and cluster seizures, with female dogs over two times more likely to achieve remission, and dogs with no previous experience of cluster seizures over six times more likely to achieve remission. No effects of neuter status or previous episodes of status epilepticus were found in any model, and were not found to improve model fit (determined by Akaike Information Criterion [AIC] and % correct classification), and as such they were not included in the final model. There were no significant effects of time until diagnosis, duration of time before treatment, the number of seizures before treatment or the seizure frequency per month before medication. No effects of follow up time or serum AED values were found. There were no significant effects of seizure type on the likelihood of remission ( $p = 0.208$ );

**Table 3.** Risk factors for remission in canine epilepsy cases.

Predictor	Odds Ratio (95% CI OR)	SE (coef)	Z	P
Sex				
Female	2.39 (1.01–5.64)	0.44	2.00	0.047
Male	Ref			
Cluster Seizures				
No	6.08 (2.35–15.70)	0.49	3.75	<0.001
Yes	ref			

doi:10.1371/journal.pone.0106026.t003

**Table 4.** Risk factors for an  $\geq 50\%$  reduction in seizure frequency in canine epilepsy cases.

Predictor	Odds Ratio (95% CI OR)	SE (coef)	Z	P
<b>Sex</b>				
Female	2.15 (1.12–4.15)	0.33	2.32	0.021
Male	<i>ref</i>			
<b>Cluster Seizures</b>				
No	4.66 (2.58–8.39)	0.30	5.14	<0.001
Yes	<i>ref</i>			
Age at onset of seizures (days)	1.00 (1.00–1.01)	0.00	2.51	0.013

doi:10.1371/journal.pone.0106026.t004

however the seizure types with the lowest remission rates were simple-focal (0% remission) and complex-focal seizure with secondary tonic-clonic generalisation (14.1% remission).

When an  $\geq 50\%$  reduction in seizure frequency is used as the outcome measure (Table 2 and 4), the same two factors were found to significantly predict the likelihood of achieving remission in a multivariate model (Table 4), with the addition of age at onset of seizures. As age at onset of seizures increases, the likelihood of achieving an  $\geq 50\%$  reduction in seizure frequency increases.

### Breeds

Dogs of fifteen different breeds achieved seizure freedom, and dogs of fifty-two breeds achieved an  $\geq 50\%$  reduction in seizure frequency. There was no statistically significant effect of breed on the likelihood of dogs going into remission or having an  $\geq 50\%$  reduction in seizure frequency when tested at the univariate level. Of the breeds with over 10 dogs for which data was available (the Labrador Retriever, Cross Breed, German Shepherd, Border Collie and Staffordshire Bull Terrier), the breed least likely to go into remission or have an  $\geq 50\%$  reduction in seizure frequency was the Border Collie (0% and 40% respectively), followed by the German Shepherd (11% and 35%) and Staffordshire Bull Terrier (0% and 57%). Fishers exact tests revealed only significant effects of being a Border Collie or German Shepherd on the likelihood of entering remission or experiencing an  $\geq 50\%$  reduction in seizure frequency (Table 5). When these breeds were included in multivariate analyses as binary variables, no significant effects were found.

### Discussion

The results of this retrospective study provide evidence that the presence of cluster seizures and thus seizure *density* (the temporal pattern of seizure activity) is a more influential risk factor on the likelihood of achieving remission in canine epilepsy than seizure

frequency or the total number of seizures prior to treatment. Nearly half (48%) of dogs in the study population had experienced cluster seizures, of which only 17.9% achieved remission and 33.5% achieved an  $\geq 50\%$  reduction in seizure frequency. This result has previously been found in human epilepsy [37]. The number of epileptic dogs that experience cluster seizures varies between studies, with recent reports between 38% and 64% [20,38]. The breed least likely to achieve remission in this study was the Border Collie, a breed previously demonstrated to have a higher level of cluster seizures than other breeds (84.6% affected) [20], with similar levels reported in other studies (e.g. 94%; [29]). A remission rate of 14.2% was observed in this study, similar to a previous Danish study of canine epilepsy (15%) [22]. These were both mixed study populations; however, in studies of Labrador Retrievers in isolation, higher levels of remission have been observed (24–40%) [19,21]. When  $>50\%$  reduction in seizure frequency is used as the outcome measure, success rates are markedly higher at 64.5%.

Seizure *density* as well as frequency has been demonstrated to influence the likelihood of remission in humans, with individuals who experience an episode of status epilepticus [39–41], or cluster seizures [37] less likely to go into remission. These results were also seen in a recent study of predictors of pharmacoresistance in rats, where the average seizure frequency per day of 13 rats nonresponsive to medication was 4.31/day, indicating some rats having cluster seizures [36]. This frequency was significantly higher than 20 drug-responsive rats (mean 0.54/day). It is further notable, that of the 13 rats that were unresponsive to medication, a subgroup of six rats (18%) experienced high levels of cluster seizures, with an average of 8.94 seizures per day [36]. Intact male and female dogs have a higher likelihood of having cluster seizures [42] which may have a negative impact on their prognosis. Evidence from canine epilepsy is not clear however, with 89% (8/9) of Border Collies in remission having a history of cluster seizures, status epilepticus, or both [29]. A severe epilepsy

**Table 5.** Top five breeds most likely to lack drug response.

Breed	% remission	p	% $\geq 50\%$ reduction	P
Border Collie	0	0.02	40	0.01
German Shepherd	11	0.51	35	0.01
Staffordshire Bull Terrier	0	0.18	57	0.37
Cross Breed	19	0.30	61	0.38
Labrador Retriever	23	0.14	76	0.07

doi:10.1371/journal.pone.0106026.t005

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.